Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center

(2020) Lukasz Kwapisz et al.   Clinical Gastroenterology and Hepatology

P090 SAFETY AND EFFICACY OF COMBINING BIOLOGICALS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

(2020) Alka Goyal et al.   GASTROENTEROLOGY

AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis

(2020) Siddharth Singh et al.   GASTROENTEROLOGY

P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study

(2020) L Goessens et al.   Journal of Crohns & Colitis

Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease

(2020) Edward Yang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tu1896 TOFACITINIB IS SAFE AND EFFECTIVE AS MONOTHERAPY OR IN COMBINATION WITH BIOLOGIC THERAPY IN PATIENTS WITH CROHN'S DISEASE

(2020) Kindra D. Clark-Snustad et al.   GASTROENTEROLOGY

Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

(2020) Ahmed Elmoursi et al.   INFLAMMATORY BOWEL DISEASES

The Use of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

(2020) Kerri Glassner et al.   Journal of Digestive Diseases

Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature

(2020) Christine Olbjørn et al.   PEDIATRIC DRUGS

Letter: combination of biologics in inflammatory bowel diseases

(2020) Mathurin Fumery et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease

(2020) Giuseppe Privitera et al.   Journal of Crohns & Colitis

S0707 The Use of Combination Vedolizumab and Ustekinumab in Crohn's Disease: A Retrospective Cohort Study

(2020) Kerri Glassner et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab

(2020) Giuseppe Biscaglia et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

(2020) William J Sandborn et al.   INFLAMMATORY BOWEL DISEASES

P717 The use of combination biologic therapy in inflammatory bowel disease: A single tertiary-centre experience

(2019) N Panaccione et al.   Journal of Crohns & Colitis

Mo1906 – Combination Therapy of Vedolizumab and Tofacitinib in IBD Patients with Chronic Active Refractory Disease Course and Spondylarthritis

(2019) Tanja Kuehbacher et al.   GASTROENTEROLOGY

Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

(2019) Davide Giuseppe Ribaldone et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Successful Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis Using Concomitant Vedolizumab and Tofacitinib: A Case Report

(2019) Joy A. Lee et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

P012 Successful Use of Combination Biologic Therapy in Medically Refractory Pediatric Crohnʼs Disease and Sacroiliitis

(2019) Julie Bass et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

(2018) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

(2018) Robert P. Hirten et al.   Clinical Gastroenterology and Hepatology

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

(2018) Lydia C T Buer et al.   INFLAMMATORY BOWEL DISEASES

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

(2018) Gary R Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy

(2018) Catherine Le Berre et al.   Clinical Gastroenterology and Hepatology

Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohnʼs Disease

(2017) Kayci Huff-Hardy et al.   INFLAMMATORY BOWEL DISEASES

P544 Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course

(2017) T. Kuehbacher et al.   Journal of Crohns & Colitis

Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy

(2017) Xavier Roblin et al.   Journal of Crohns & Colitis

P514 Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data

(2017) L. Buer et al.   Journal of Crohns & Colitis

Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease

(2016) Clara Yzet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease

(2015) Robert Hirten et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Assessing Bias in Studies of Prognostic Factors

(2013) Jill A. Hayden et al.   ANNALS OF INTERNAL MEDICINE

Review article: remission rates achievable by current therapies for inflammatory bowel disease

(2011) L. Peyrin-Biroulet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS